Inherited Thrombophilia

Inherited thrombophilia refers to a group of genetic conditions that increase the body’s tendency to form blood clots. These inherited mutations disrupt the natural balance between coagulation and anticoagulation, tipping the balance toward hypercoagulability. While many people with these variants never experience a clot, the risk rises substantially in the presence of other factors such as surgery, immobility, hormonal contraception, pregnancy, or chronic illness. For women, in particular, inherited thrombophilia is an underrecognized cause of recurrent venous thromboembolism, miscarriage, and long-term vascular complications.

Overview

What is an inherited thrombophilia?

Inherited thrombophilia is defined by a genetic defect that alters coagulation proteins or reduces the body’s ability to regulate clot breakdown. These disorders are inherited in an autosomal dominant or, more rarely, autosomal recessive pattern. The resulting imbalance leads to increased activation of the clotting cascade or resistance to natural anticoagulant mechanisms.

Although most cases are clinically silent, inherited thrombophilia often becomes apparent after deep vein thrombosis (DVT), pulmonary embolism (PE), or an unexplained clot in an unusual site, such as the cerebral, splanchnic, or retinal veins. Women are particularly vulnerable during hormone replacement therapy (HRT), pregnancy, and the postpartum period, when physiological hypercoagulability intensifies.

---

Inherited Thrombophilia

How many different types of inherited thrombophilia are there?

Major inherited thrombophilias are genetic disorders that significantly increase an individual’s lifelong risk of developing venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). These conditions are defined by specific mutations that alter the body’s natural balance between clot formation and dissolution, tipping the hemostatic system toward hypercoagulability. They are among the most well-studied hereditary contributors to vascular disease, often running silently through generations until triggered by factors such as surgery, pregnancy, hormonal therapy, or immobility. While the five classical forms account for the majority of genetically linked clots, their presentation varies widely across age, sex, and exposure to acquired risk factors.

Factor V Leiden Mutation

The most common inherited cause of thrombophilia, Factor V Leiden, results from a single point mutation (G1691A) in the F5 gene. This change makes factor V resistant to inactivation by activated protein C (APC), allowing unchecked thrombin generation. Approximately 5% of Caucasians carry the mutation, and heterozygotes have a 3–8 fold increased risk of venous thromboembolism (VTE). The risk rises up to 80-fold in homozygous individuals or when combined with estrogen exposure or pregnancy.

Prothrombin G20210A Mutation

A mutation in the F2 gene increases prothrombin (factor II) production, elevating baseline thrombin levels and predisposing to clot formation. Found in about 2% of the general population, it doubles to triple the risk of venous thromboembolism (VTE). The mutation is also associated with cerebral venous sinus thrombosis (CVST) and splanchnic vein thrombosis, particularly in women using hormonal contraception.

Protein C Deficiency

Protein C is a vitamin K-dependent anticoagulant that deactivates factors Va and VIIIa. Deficiency can be quantitative (Type I) or qualitative (Type II) and may occur in heterozygous or homozygous forms. Heterozygous carriers of protein C deficiency have a 7–10 fold higher risk of venous thrombosis, while homozygous forms are often fatal in infancy due to purpura fulminans, a severe neonatal clotting disorder.

Protein S Deficiency

Protein S functions as a cofactor for activated protein C. Protein S deficiency reduces anticoagulant efficiency, leading to unopposed thrombin activity. It affects 1 in 300 to 500 individuals and may be inherited or acquired. In women, estrogen use further suppresses protein S levels, dramatically amplifying clotting risk.

Antithrombin Deficiency

Antithrombin inhibits several activated clotting factors, including thrombin (factor IIa) and factor Xa. Antithrombin deficiency—whether due to reduced quantity or impaired function—creates a potent hypercoagulable state. Though rare (present in roughly 1 in 5,000 people), it is one of the most severe inherited thrombophilias, with up to a 50% lifetime risk of venous thromboembolism (VTE).

Dysfibrinogenemia

This rare disorder results from qualitative defects in fibrinogen, the protein that forms the structural framework of clots. Abnormal fibrinogen can cause both bleeding and thrombosis, depending on the mutation. Dysfibrinogenemia is clinically significant when combined with inflammatory or hepatic disorders.

Elevated Factor VIII and IX Levels

High baseline levels of factor VIII or IX can be inherited and persistently elevate thrombotic risk. These factors amplify thrombin generation and impair fibrinolysis. Women with genetically elevated factor VIII experience higher rates of deep vein thrombosis (DVT) and pulmonary embolism (PE), especially when compounded by obesity or estrogen therapy.

Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G Polymorphism

This common genetic variation affects fibrinolysis—the process that dissolves clots. The 4G allele increases PAI-1 expression, reducing the body’s ability to break down fibrin. Carriers of the 4G/4G genotype have a measurable rise in venous thromboembolism (VTE) risk and may experience recurrent thrombosis despite anticoagulation.

Methylenetetrahydrofolate Reductase (MTHFR) Variants

The C677T and A1298C variants in the MTHFR gene can lead to elevated homocysteine levels, which damage vascular endothelium and promote platelet aggregation. While MTHFR mutations alone are not considered a major independent cause of thrombosis, the presence of hyperhomocysteinemia increases risk, particularly in women with nutritional deficiencies in folate, B6, or B12.

---

Emerging and Rare Inherited Thrombophilia

While the five primary hereditary thrombophilias account for most genetically driven clotting disorders, several additional and less common mutations are now recognized for their contribution to persistent or unexplained hypercoagulability. These variants often affect fibrinolysis, the body’s ability to break down clots, or alter other anticoagulant pathways. Although individually rare, their cumulative impact is significant in patients with recurrent or atypical thrombosis despite normal routine testing.

Congenital Dysplasminogenemia (Plasminogen Deficiency)

A deficiency or dysfunction of plasminogen impairs fibrinolysis, allowing thrombi to persist and propagate. This rare condition (estimated prevalence 1 in 1,000,000) can lead to recurrent deep vein thrombosis (DVT) or pulmonary embolism (PE), often in the absence of traditional risk factors.

Elevated Lipoprotein(a)

Genetically determined elevations in lipoprotein(a) [Lp(a)] interfere with normal fibrinolysis by competing with plasminogen binding sites on fibrin. Elevated Lp(a) levels are present in up to 20% of the population and markedly increase the risk of both arterial and venous thrombosis. In women, Lp(a) also amplifies risk when combined with insulin resistance or postmenopausal estrogen decline.

Congenital Hypodysfibrinogenemia

A dual quantitative and qualitative fibrinogen defect that leads to abnormal fibrin polymerization. Though extremely rare, it can cause both bleeding and thrombosis depending on the specific mutation. Thrombotic presentations are typically associated with hepatic dysfunction or systemic inflammation.

Factor XII (Hageman Factor) Deficiency

Traditionally considered a bleeding disorder, this deficiency paradoxically increases thrombosis risk by disrupting fibrinolytic activation and contact pathway regulation. Factor XII deficiency has been identified in idiopathic venous thrombosis, particularly among women with coexisting PAI-1 elevation.

Heparin Cofactor II Deficiency

Heparin cofactor II inhibits thrombin in a heparin-dependent manner. Congenital deficiency, while rare, diminishes the body’s natural antithrombotic defense and has been linked to early-onset venous thromboembolism (VTE) in families with otherwise negative thrombophilia panels.

α2-Antiplasmin Deficiency

A defect in this major plasmin inhibitor leads to excessive fibrinolysis followed by rebound hypercoagulability as thrombin generation increases. Though exceedingly rare, it highlights the delicate equilibrium between clot formation and dissolution that defines thrombotic biology.

These variants illustrate that inherited thrombophilia is not confined to the classic five conditions but represents a broader continuum of genetic and vascular dysregulation. Recognizing and testing for these rarer forms can be crucial in patients—especially women—with recurrent, unexplained, or unusual-site thrombosis despite conventional negative workups.

---

Emerging Genetic Risk Modifiers

While the primary inherited thrombophilias are defined by well-characterized mutations that directly alter coagulation proteins, modern genomic research has revealed a broader spectrum of genetic polymorphisms that influence the body’s clotting balance in more subtle ways. These variants do not typically cause thrombosis on their own and are not classified as “classical inherited thrombophilias.” Instead, they act as genetic amplifiers, increasing the likelihood or severity of thrombotic events when combined with other risk factors, such as inflammation, hormonal therapy, or metabolic disease.

For women in particular, these genetic modifiers can become clinically significant during periods of physiological stress or hormonal change, when endothelial and coagulation pathways are already activated. Their recognition is reshaping how physicians interpret “borderline” thrombophilia panels that show normal protein levels but unexplained clotting patterns.

Below are the most studied emerging genetic contributors to hypercoagulability:

SERPINC1 Polymorphisms (Borderline Antithrombin Variants)

Minor variants within the SERPINC1 gene can subtly reduce the activity or stability of antithrombin without causing a full quantitative deficiency. These individuals may have near-normal antithrombin levels but demonstrate exaggerated thrombin generation during high-estrogen states, infection, or surgery. Recent molecular data suggest that such variants explain a portion of “unexplained” venous thromboembolism in women with normal laboratory profiles.

THBD (Thrombomodulin) Gene Mutations

Thrombomodulin, an endothelial surface protein, plays a crucial role in activating protein C and maintaining anticoagulant signaling. Mutations in the THBD gene disrupt this function, leading to excessive thrombin activity and impaired regulation of the coagulation cascade. These mutations have been linked to atypical venous thrombosis and recurrent early pregnancy loss, conditions where standard thrombophilia testing is often negative.

F13A1 Variants (Factor XIII Polymorphisms)

Factor XIII stabilizes fibrin by cross-linking fibrin strands, producing a clot that resists premature breakdown. Certain polymorphisms in the F13A1 gene lead to hyperstable fibrin that is abnormally resistant to fibrinolysis. Although rare, these variants have been associated with recurrent deep vein thrombosis (DVT) and arterial thrombosis in younger patients, particularly women with concurrent PAI-1 elevation or metabolic syndrome.

PROC and PROS1 Functional Polymorphisms

Beyond classical protein C or S deficiency, subclinical variants in the PROC and PROS1 genes can reduce anticoagulant efficiency without significantly lowering circulating protein levels. These polymorphisms often manifest only under additional stressors such as inflammation, estrogen therapy, or pregnancy. Patients with these variants may show normal results on standard assays but exhibit persistent hypercoagulability on advanced thrombin-generation testing.

These emerging polymorphisms illustrate how genetic risk for thrombosis exists along a continuum, from the clearly pathogenic to the functionally subtle. For clinicians and patients, especially women with unexplained clotting or strong family histories, understanding these variants underscores an evolving truth: thrombosis is rarely the product of a single mutation, but rather the cumulative effect of genetic predisposition, hormonal signaling, inflammation, and environmental stressors acting together on a shared vascular system.

---

The Broader Genetic Landscape of Thrombosis

Inherited thrombophilia represents only a fraction of the full genetic landscape influencing thrombosis. While the classic five mutations account for roughly 50–60% of familial clotting disorders, recent genomic studies show that up to one in three patients with unexplained venous thromboembolism (VTE) carry one or more subtle variants that affect fibrinolysis, endothelial signaling, or coagulation regulation. These findings dismantle the traditional binary of “positive” or “negative” thrombophilia results, revealing that most thrombosis risk exists on a continuum shaped by dozens of interacting genetic and environmental factors.

For women, this complexity has direct clinical consequences. Female patients are disproportionately underdiagnosed and undertested for inherited or functional hypercoagulability despite facing three times greater lifetime exposure to prothrombotic states through pregnancy, hormonal contraception, and menopause. According to recent data published in Blood Advances (2024), up to 40% of women who experience a pregnancy-associated pulmonary embolism test negative on standard thrombophilia panels but exhibit abnormal thrombin generation or PAI-1 levels when advanced assays are performed. These “invisible” abnormalities, once dismissed as idiopathic, are now understood to represent the genetic and vascular middle ground between normal and disease.

The growing recognition of rare and emerging genetic risk modifiers demands a paradigm shift in how thrombosis is screened and prevented. Identifying these hidden predispositions is about restoring accountability to a diagnostic system that too often labels preventable vascular deaths as unexplainable. As genomic sequencing and functional testing become more accessible, the future of thrombosis prevention lies not in isolated mutation hunting, but in mapping each individual’s comprehensive coagulation fingerprint, providing a blueprint that could transform how we predict, prevent, and ultimately stop the world’s most overlooked cause of sudden death.

---

The IWBCA provides the information and materials on this site for educational and informational purposes only. The content is not a substitute for professional medical evaluation, diagnosis, or treatment. Always consult your physician or another qualified healthcare provider regarding any questions you may have about a medical condition, diagnosis, or course of treatment. Do not disregard, delay, or alter medical advice based on information obtained from this site. If you believe you are experiencing a medical emergency, call 911 or your local emergency services immediately.